Jim Simons Otonomy, Inc. Transaction History

Renaissance Technologies LLC

  • $63.1 Billion
  • Q3 2024

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$0.25 - $2.24 $3,000 - $26,880
12,000 Added 3.61%
344,726 $102,000
Q2 2022

Aug 12, 2022
BUY
$1.72 - $2.51 $20,124 - $29,366
11,700 Added 3.64%
332,726 $692,000
Q1 2022

May 13, 2022
SELL
$1.72 - $2.47 $3,096 - $4,446
-1,800 Reduced 0.56%
321,026 $770,000
Q4 2021

Feb 11, 2022
SELL
$1.69 - $2.31 $476,749 - $651,651
-282,100 Reduced 46.63%
322,826 $671,000
Q3 2021

Nov 12, 2021
SELL
$1.22 - $2.2 $144,082 - $259,820
-118,100 Reduced 16.33%
604,926 $1.16 Million
Q2 2021

Aug 13, 2021
BUY
$2.06 - $2.67 $49,771 - $64,509
24,161 Added 3.46%
723,026 $1.61 Million
Q1 2021

May 13, 2021
SELL
$2.49 - $6.23 $1.75 Million - $4.38 Million
-703,700 Reduced 50.17%
698,865 $1.78 Million
Q4 2020

Feb 10, 2021
SELL
$3.48 - $6.47 $884,964 - $1.65 Million
-254,300 Reduced 15.35%
1,402,565 $9.08 Million
Q3 2020

Nov 13, 2020
SELL
$3.16 - $4.36 $613,040 - $845,840
-194,000 Reduced 10.48%
1,656,865 $6.71 Million
Q2 2020

Aug 13, 2020
SELL
$1.87 - $3.84 $134,827 - $276,864
-72,100 Reduced 3.75%
1,850,865 $6.7 Million
Q1 2020

May 14, 2020
SELL
$1.58 - $4.06 $26,860 - $69,020
-17,000 Reduced 0.88%
1,922,965 $3.79 Million
Q4 2019

Feb 13, 2020
BUY
$2.13 - $3.83 $466,674 - $839,137
219,096 Added 12.73%
1,939,965 $7.43 Million
Q3 2019

Nov 13, 2019
SELL
$2.12 - $2.86 $4,341 - $5,857
-2,048 Reduced 0.12%
1,720,869 $4.11 Million
Q2 2019

Aug 12, 2019
BUY
$2.35 - $3.09 $201,087 - $264,408
85,569 Added 5.23%
1,722,917 $4.74 Million
Q1 2019

May 14, 2019
BUY
$1.8 - $2.97 $483,312 - $797,465
268,507 Added 19.62%
1,637,348 $4.31 Million
Q4 2018

Feb 13, 2019
BUY
$1.51 - $2.93 $2.07 Million - $4.01 Million
1,368,841 New
1,368,841 $2.53 Million

About OTONOMY, INC.

OTIC Quotes by TradingView
  • Ticker OTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,990,400
  • Description
  • Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...
More about OTIC
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email